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ABSTRACT 
The overall aim of this thesis is to investigate whether drug treatment is 
unequally distributed among older adults on the basis of age and socioeconomic 
position. 
All studies in this thesis are based on nationwide register data from the Swedish 
Prescribed Drug Register (SPDR) record-linked to other registers in Sweden.  
In Study I, we investigated differences in drug use between centenarians (≥100 
years; n=1,672), nonagenarians (90-99 years; n=76,584) and octogenarians (80-
89 years; n=383,878). The results showed that the proportion of people living in 
institutions increased with age, but the number of drugs was similar across the 
age groups. Centenarians were more likely to use psychotropics 
(hypnotics/sedatives, antidepressants and anxiolytics) and pain killers (minor 
analgesics and opioids). This might indicate that drug treatment has a more 
palliative character in centenarians than in the other age groups. Centenarians 
used older types of cardiovascular drugs which could reflect a lack of regular re-
evaluation of drug use in centenarians or a disinclination to make changes in 
well-functioning drug therapy among the extremely old. 
The aim of Study II was to investigate educational differences (as a measure of 
socioeconomic position) in osteoporosis drug use before and after osteoporosis-
related fractures among persons aged 75-89 years (n=645,429). There is a 
general underuse of osteoporosis drugs among older adults in Sweden. Our 
results suggest that older persons with lower levels of education are less likely to 
receive drug treatment both before and after an osteoporosis-related fracture 
(only statistically significant in women) than their more highly educated 
counterparts. The educational differences were more pronounced for newer and 
more potent osteoporosis drug treatments. Lower socioeconomic position seems 
to be linked to a lower use of osteoporosis drugs – a drug therapy that is 
generally underused. 
In Study III, the aim was to investigate educational differences in antipsychotic 
drug use among older adults (aged 75-89 years) with and without dementia 
  
(n=641,566). Antipsychotic drugs are commonly used to treat behavioral and 
psychological symptoms of dementia, but the use of these drugs has been 
associated with increased morbidity and mortality. Efforts have therefore been 
made to reduce the prescribing of antipsychotic drugs to older adults with 
dementia. We found a higher use of antipsychotic drugs among persons with 
lower levels of education, both among persons with and without dementia. 
Lower socioeconomic position seems to be positively associated with a higher 
use of antipsychotic drugs – a drug therapy that is generally overused. 
We investigated educational differences in being prescribed psychotropic drugs 
by specialist physicians among older (aged 75-89 years) psychotropic drug users 
(n=221,579) in Study IV. Higher levels of education were associated with more 
access to geriatrician and psychiatrist prescribing. However, when place of 
residence was taken into account, the association between higher education and 
psychotropic prescription by geriatricians became non-significant, whereas the 
association between higher education and prescription by psychiatrists persisted. 
Limited access to specialists could be one mechanism liking lower 
socioeconomic position to less optimal drug treatment. 
This thesis contributes to a better understanding of how socioeconomic position 
and age are related to drug use. In general, lower socioeconomic position and 
older age seem to be associated with less optimal drug treatment. However, the 
mechanisms behind these findings are probably complex and need to be 
addressed in further research to provide a foundation for social policy. 
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1 INTRODUCTION 
During the last 250 years, life expectancy has increased in western Europe, and it 
is expected to increase even further.
1
 The ageing population is indeed a success 
story, as more people are living longer. In Sweden, 2.4% of the population was 
80 years or older in 1970, 5.2% by 2013, and the share is expected to grow even 
further in the future.
2
 The number of extremely old persons has also risen 
rapidly; there has been a 7-fold increase in the number of centenarians since the 
1970s.
3
 At the same time as life expectancy has risen, the mortality gap between 
persons with higher and lower levels of education has also increased during the 
last three decades.
4
 
It is unclear whether the increase in life expectancy has been attained through the 
addition of more healthy or more sick years. Some evidence suggests that 
disability has been postponed but chronic conditions have increased.
5, 6
 Part of 
the trend toward an increased number of chronic conditions can be attributed to 
increased medical knowledge, more preventive treatments and earlier dignoses. 
Many ‘silent diseases and conditions’ such as osteoporosis, diabetes and 
hypertension,
5
 are now detected and treated earlier, before they lead to functional 
limitations. 
The earlier detection of diseases and the increased number of available 
treatments have led to increased use of pharmaceutical drugs (Figure 1).
7
 In 
Sweden, people aged 80 years and older use on average five drugs concurrently.
8
 
Treating older adults with drugs is a challenge because of age-related 
physiological changes and high levels of co-morbidities.
9
 The concurrent use of 
many drugs among the oldest old has been criticised,
10
 and polypharmacy has 
been linked to an increased risk of inappropriate drug use
11
 and adverse drug 
events,
12
 which ultimately can lead to hospitalisation.
13, 14
 The challenge is to 
balance potentially valuable drug therapy against the risk of adverse events. 
Health and disease is socially patterned, and generally, more well-off people 
have better health.
4, 15
 Access to health care is one factor that can contribute to 
the health divide between socioconomic groups.
16
 Studies show that more 
 2 
advantaged people have greater acess to health care and use it more frequently.
17, 
18
 On the other hand, research shows that disadvantaged people have a higher 
risk of potentially inappropriate drug treatment
19
 and of being prescribed drugs 
in a manner that does not follow guidelines in Sweden.
20, 21
 Furthermore, 
disavantaged people have a smaller chance of receiving potentially valuable drug 
therapy,
22
 receiving newer
23
 and more expensive drugs
24
 and of being prescribed 
drugs by specialist physicians in old age.
25
 
 
Figure 1. Number of items dispensed in Sweden, 2000-2013. Source: LIF, Fakta 
2014. 
Given that an increasing number of older adults are living longer with chronic 
conditions, and that this development is accompanied by increased and 
prolonged drug use, equal access to health care and drug treatment is of growing 
importance. Thus, the overarching aim of the present thesis was to investigate 
whether drug treatment is unequally distributed among older adults on the basis 
of age and socioeconomic factors. 
  3 
1.1 DRUG UTILISATION RESEARCH 
Drug utilisation research is part of the wider field of pharmacoepidemiology.
26
 
Recently, drug utilisation research has been defined as “an eclectic collection of 
descriptive and analytical methods for the quantification, the understanding and 
the evaluation of the processes of prescribing, dispensing and consumption of 
medicines, and for the testing of interventions to enhance the quality of these 
processes” (Wettermark et al 2008).27 
This thesis uses the multidisciplinary framework of drug utilisation research to 
focus on how social stratification (age and socioeconomic factors) affects 
inequality in drug use, as depicted in Figure 2. 
 
Figure 2. Multidisciplinary perspective on inequality in drug use. Modified from 
Wettermark et al. 2014.
28
  
Drug utilisation research encompasses elements of both pharmacoepidemiology 
and health care research. A division between descriptive and analytical drug 
utilisation research is sometimes made.
29
 Descriptive drug use research 
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undertakes to describe patterns and trends. Analytical drug use research further 
tries to evaluate whether the drug use is rational when different outcomes of drug 
use are considered (morbidity, mortality etc.). An additional feature of analytical 
drug use research is the investigation of potential mechanisms behind the 
patterns of drug use. 
29
 Elements from both descriptive and analytical drug use 
research are incorporated in this thesis. 
1.2 DRUGS AND AGEING 
Ageing is often accompanied by many diseases and symptoms. When two or 
more conditions are present at the same time, the person is said to have 
multimorbidity
30
 or complex health problems.
31
 Increasing rates of co-morbidity 
are often followed by an increase in drug use. Women tend to live longer than 
men but to have more health problems, the so-called male-female health-survival 
paradox.
32
 Similarly, men tend to have fewer health problems, but more life-
threatening conditions.
33
 Women also tend to use more drugs than men in old 
age.
34
 
Older adults are rarely included in randomised clinical drug trials, especially if 
they have more than one disease.
35
 There is therefore little evidence of the 
effects and side-effects of most drugs among older adults, and concurrent 
treatment with many different drugs may even be considered an experiment. 
The literature also indicates that older age often is linked to lower quality of drug 
treatment. Older age tends to increase the risk of inappropriate drug use,
11
 
adverse drug effects
36
 and having older medications.
8
 However, given that new 
drugs are rarely tested on older adults and that older adults can have a lower 
tolerability of drugs, cautious prescribing of newer drugs in clinical practice can 
be warranted. 
1.2.1 Pharmacological aspects of drug intake in old age 
In the ageing body, physiological changes alter the body’s response to drug 
treatment, and coexisting diseases can further complicate prescribing. The 
physiological changes in the body, which include reduced organ function, often 
  5 
mean that the effects of a drug are prolonged and/or increased. The challenge is 
to balance the risk of unintended adverse effects of drugs without denying older 
people valuable drug therapy. 
1.2.1.1 Pharmacokinetics 
Pharmacokinetics can be described as ‘what the body does to the drug’. 
Pharmacokinetic changes in the body can affect the ability to absorb, distribute, 
metabolise and excrete drugs.
37
 With ageing, the proportion of body water is 
reduced, which leads to an increase in the proportion body fat. This increase 
gives fat-soluble drugs a larger volume of distribution, which can lead to a 
prolonged effect and consequently a risk of adverse drug effects.
9
 
Renal function is also reduced in old age. This limits the body’s ability to excrete 
drugs. As a result, drugs can accumulate in the body, which can cause adverse 
events.
38
 It is thus important to take renal function into account when 
administering drugs to older adults. 
1.2.1.2 Pharmacodynamics 
Pharmacodynamics can be described as ‘what the drug does to the body’. In old 
age, sensitivity to drugs can increase because of changes in organ systems. For 
example, old persons’ tolerance of psychotropic drugs can decrease because the 
brain becomes more sensitive to drugs that act on the central nervous system. 
Changes in the gastrointestinal organs also lead to an increased risk of 
gastrointestinal bleeding.
37
  
1.2.2 Drug utilisation in old age 
A panel of 12 experts in geriatric care ranked pharmacological management as 
the number one target area for quality improvement among a set of geriatric 
conditions. The ranking by Sloss et al. 2000
39
 was based on: “1) prevalence, 2) 
impact on health and quality of life, 3) effectiveness of interventions in reducing 
mortality and improving quality of life, 4) disparity in the quality of care across 
providers and geographic areas and 5) feasibility of obtaining the data needed to 
test compliance with quality indicators”.39 Other conditions ranked as good 
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targets for quality improvements were: depression (2), dementia (3), heart failure 
(4), falls and mobility disorders (7) and osteoporosis (13). 
1.2.2.1 Number of drugs and age 
In general drug use increases with age; only 10% of the Swedish population 
between the ages of 20 and 29 use 5 or more prescribed drugs in one year, 
whereas almost 80% of the population between the ages of 80 and 89 years do 
so.
40
 However, after age 80, the use of prescribed drugs seem to level off (Figure 
3).
8
  
 
Figure 3. Number of dispensed drugs (unpublished data from Study I). 
1.2.2.2 Osteoporosis 
Osteoporosis is a disease that makes bone fragile and increases the risk for 
fractures. The prevalence of osteoporosis increases with age, and the disease is 
common among older adults. Sweden has among the highest incidences of 
osteoporosis in the world:
41
 nearly half the women and one fifth of the men 
between the ages of 80 and 84 years are affected.
42
 The Swedish Council on 
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Technology Assessment in Health Care has estimated that osteoporosis causes 
70,000 fractures a year in Sweden.
43
 Osteoporosis and subsequent fractures lead 
to great societal costs and reduced quality of life among older adults.
44
 
Older age has been associated with a higher risk of being undertreated with 
osteoporosis drugs.
45
 Women are more likely to have osteoporosis and 
subsequent fractures than men, but mortality after most osteoporotic fractures is 
higher among men.
46
 The findings regarding socioeconomic position (SEP) are 
mixed. Two related reviews found that low SEP was associated with higher risk 
of low bone density in women but not in men
47
 but found no association between 
SEP and osteoporotic fractures.
48
 
The three main osteoporosis drug treatments are calcium/vitamin D 
combinations (also available as over-the-counter drugs), bisphosphonates and 
selective estrogen receptor modulators (SERMs) (only used in women). 
Osteoporosis drug treatment can be initiated both to prevent an osteoporosis-
related fracture and as secondary prevention after an osteoporosis-related 
fracture. The effectiveness of osteoporosis drugs has actually been documented 
in randomised controlled trials in older adults.
49, 50
 Calcium/vitamin D 
combinations are the least potent of the drugs, and the more newly marketed 
drugs (bisphosphonates and SERMs) are used in more severe cases of 
osteoporosis. SERMs are hormone-adjusting drugs that are only used in women. 
In recent years, researchers have questioned the use of SERMs for treating 
osteoporosis because of the increased risk for venous thromboembolism and 
stroke.
51
 A number of researchers have argued that there is a general 
undertreatment with osteoporosis drugs,
45, 52, 53
 especially among men.
54
 A few 
studies have investigated whether the use of osteoporosis drugs differs between 
socioeconomic groups, with mixed results.
55-58
 
1.2.2.3 Mental health 
Mental disorders are common among older adults; among persons aged 75 years 
or older, approximately one in four has a mental disorder
59
 or psychological 
distress.
60
 Mental disorders include several diseases and symptoms (e.g. 
 8 
depression, anxiety and mood disorders). Many mental disorders may be 
underdiagnosed among older adults because the symptoms are sometimes 
different in older adults than younger persons (e.g. the symptoms of 
depression).
61
 
In older adults, mental disorders are mainly treated with psychotropic drugs. 
Psychotropics can be divided into antipsychotics, anxiolytics, hypnotic sedatives 
and antidepressants. Psychotropics are mainly prescribed to older adults by 
general practitioners (GPs) who work in outpatient care (in the Swedish health 
care system, GPs undergo a specialist education in family medicine.).
62
  The 
Swedish system, in which GPs prescribe the majority of psychotropics, has been 
criticised.
62
 Many GPs may not have sufficient knowledge about the specific 
symptoms of mental disorders in old age, and psychotropic prescribing may be 
further complicated by the multimorbidity and lower tolerance of drugs among 
older adults.  
1.2.2.4 Behavioural and psychological symptoms of dementia  
Behavioural and psychological symptoms of dementia (BPSD) include a range 
of behaviours and symptoms such as screaming, wandering and hallucinations.
63
 
The concept of BPSD has been criticised as non-specific, and there is no 
consensus about what constitutes BPSD.
63
 
It has been estimated that almost 90% of people with dementia experience some 
kind of BPSD during the progression of the disorder.
64
 In clinical practice, 
antipsychotics have often been used to treat many of these symptoms.
65
 
However, around 2005, a series of studies found that antipsychotics increase the 
risk of morbidity and mortality among older adults with dementia,
66-69
 and since 
then their use in institutional settings has declined from 17% to 13%.
70
 
In the current Swedish guidelines developed by the National Board of Health and 
Welfare, antipsychotics are not recommended as a first-line treatment for BPSD. 
Rather, the guidelines call on social and health care professionals to first rule out 
all causes of BPSD, such as suboptimal pain treatment and problems in the care 
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environment. Non-pharmacological treatments are thus the first-line 
treatments.
71
 
One study on the association between SEP and antipsychotic drug use among 
older adults with dementia in Canada found that those with lower income were 
more likely to be treated with potentially inappropriate antipsychotics.
72
 A report 
from the Swedish National Board of Health and Welfare also indicates that the 
use of antipsychotics is more common in persons with dementia who have a low 
level of education and/or were born outside Sweden than in those with dementia 
who have a high level or education and/or were born in Sweden.
70
 
1.3 SOCIAL STRATIFICATION 
Most societies have some principle of social stratification. That is, a system of 
social positions in which some people have more resources and better life 
chances than others. The principles of stratification can change over time and 
across regions. This thesis focuses on socioeconomic stratification, measured as 
educational level. 
1.3.1 Social inequalities in health 
There is a vast literature on the association between SEP and health, and most 
health conditions seem to follow a social gradient whereby every step lower in 
the social hierarchy is linked to worse health.
15
 Socioeconomic inequalities in 
health are one of the most consistent findings in social epidemiology and seem to 
persist across time and regions.
15, 73-75
 Moreover, these inequalities in health 
seem to persist into old age.
76, 77
 However, the mechanisms behind the 
relationship are not fully understood. For summaries of the mechanisms, see 
Mackenbach 2012
78
 and Bambra 2011
79
. 
A common typology divides the mechanisms into material, psychosocial and 
behavioural.
80, 81
 Material explanations emphasise differences in material living 
standards and consumption. Psychosocial explanations emphasise the 
psychological and physiological responses to stress that can arise from feeling 
disadvantaged. Behavioural explanations focus on the social patterning of 
 10 
behaviours and lifestyles and the higher frequency of poor habits among less 
advantaged persons. 
It has also been proposed that the association between SEP and health may be 
due to health selection processes. This explanation implies that poor health 
results in a less advantaged social position rather than the other way around; i.e., 
a person with poor health will not have the same opportunities to have an 
education, get a job and/or earn a high income. Other researchers have 
questioned the hypothesis that selection processes may be the main driver of the 
general socioeconomic differences in health,
82
 although health selection will 
have some impact on income and occupation because it is clearly related to the 
ability to work.
83
 
1.3.1.1 The fundamental cause theory of health inequalities 
A more recent theory on the mechanism behind socioeconomic differences in 
health is the fundamental cause theory of health inequalities. Phelan and Link 
first formulated the theory in 1995,
73
 and it has been developed further since 
then.
84-88
 The theory is foremost an attempt to explain the persistence of health 
inequalities across time and regions, but the theory also contextualise the ways in 
which access to and use of health care and medical treatments can contribute to 
health inequalities. 
The persistence of a social gradient in health has been robust over time, 
irrespective of the radical changes in life expectancy, disease panorama and risk 
factors over the last century. Furthermore, neither the expansive welfare states 
nor the technical innovations in health care have been able to eradicate the 
association. Rather, it seems that the more developed welfare states and health 
care systems have enlarged the relative differences between social groups.
78
 
According to Phelan and Link, controlling disease and morbidity through health 
care advances is not likely to remove the social differentials in health; rather, 
advantaged persons are more likely to benefit more from the advances made.
86
 
Thus, the socioeconomic difference is likely to be larger for diseases that are 
preventable. Some studies have shown that the socioeconomic differences in 
  11 
mortality are larger for amendable conditions,
87, 89
 but these findings have not 
been replicated in all studies.
90
 Further, it has also been shown that health 
technological innovations may increase inequalities in health, since highly 
educated persons are more likely to access and exploit the new technologies.
91
 
For example, in the United States, cholesterol levels were higher in high than 
low SEP groups before the introduction of statins, but after statins achieved wide 
use in high SEP groups, the relationship between SEP and cholesterol reversed.
92
 
According to the fundamental cause theory, people with higher SEP use their 
flexible resources (such as money, knowledge, prestige, power and beneficial 
social connections) to gain faster access to care, obtain better health information 
and avoid risks. Thus, irrespectively of what new mechanism linking SEP to 
health that emerges, more advantaged persons will use their flexible resources to 
attain a health advantage over persons in lower social strata.  
Material resources are used to buy health-enhancing services and items. Social 
resources are important to obtaining health-related information, informal care 
and access to providers. Cognitive resources can be used to gain and assess 
health-related advice, avoid risks and orient oneself in the health care system.
93
 
People with many resources also tend to socialise with people who are more 
health-aware (through workplaces, institutions and neighbourhoods), which can 
have a positive influence on health behaviours.
93
  
1.3.1.2 Educational level as an indicator of socioeconomic position 
Socioeconomic conditions are often measured through SEP. SEP can be 
measured with indicators, such as income, social status, occupation and 
education.
94
 The different measures of SEP are often used interchangeably but 
have different theoretic underpinnings and can also point to different underlying 
mechanisms.
94-96
 
As an indicator of SEP, education has some specific properties. First, it is usually 
the SEP indicator attained earliest in life, which reduces some of the risk of 
health selection biases.
94
 Poor health in mid-life can lead to the loss of a job or 
income, whereas education remains constant. Second, since education is 
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sometimes a prerequisite for entry into the labour market and for a high income, 
education will also be a partial marker of occupation and income. However, 
there are selections into education that are not necessarily related to SEP. For 
instance, in older cohorts, few people – and in particular, few women – had the 
opportunity to obtain a higher level of education. Education is also an indicator 
of immaterial resources and is linked to factors such as lifestyle behaviours, 
habits, social relationships and cognitive abilities.
78, 97, 98
 Education also has an 
impact on individuals’ health-related knowledge, health literacy and ability to 
demand care.
99
  
Assessing the SEP of older people is difficult for a number of reasons.
100
 Older 
adults are often retirees, so it is not possible to assign them an occupation (if not 
asked in retrospect or using administrative data on last/main occupation). 
Further, for retirees, pensions are the main source of income, and most pension 
systems tend to equalise the income distribution. Thus, wealth may be a better 
indicator of older people’s financial resources than income.101 Further, the 
relative importance of different indicators of SEP might vary over time. For 
instance, general educational attainment was low at the beginning of the 
twentieth century, and few had more than a basic education. Future cohorts of 
older adults will have higher levels of education, and this will lead to 
compositional changes that might affect the associations between education and 
a variety of outcomes.
102
 
1.4 THE SWEDISH HEALTH CARE SYSTEM AND INEQUALITY 
1.4.1 The Swedish health care system 
In Sweden, the state is responsible for health policy, whereas the county councils 
(n=20) and municipalities (n=290) are responsible for funding and provision of 
services. The county councils are responsible for health care, which is financed 
through taxation.
103
 Care for older adults is, however, mainly performed and 
financed by the municipalities.
103
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1.4.1.1 Primary care 
In Sweden, primary care is foremost provided by GPs. The physicians working 
as GPs in Sweden are most often specialists in family medicine 
(‘allmänläkare’).62 The patient can choose any public or private provider 
accredited by the county councils.
103
 A visit to the GP is usually the first contact 
that older adults with physical or psychological problems have with the health 
care system. For older adults, the district nurse is also a common first health-care 
contact. District nurses are most often employed by the municipalities but act 
under the supervision of a physician. District nurses regularly make home visits 
and have the right to prescribe some drugs.
103
 
1.4.1.2 Specialised care 
Specialised care, which requires more medical equipment and technology, is 
mainly provided at hospitals. The most specialised and advanced care is 
provided at the seven university hospitals, and more regular specialised care is 
provided at about 70 local hospitals. About two-thirds of the hospitals have 24- 
hour acute care. The number of acute care settings has decreased continuously 
over the last decades, and during this time there has been a move from hospital 
inpatient care to outpatient care. For example, outpatient care at hospitals has 
grown; that is, treatment or surgery for conditions that do not require an 
overnight stay.
103
 
1.4.1.3 Inequality in health care 
The Swedish Health Care Act states that access to health care should be equal 
and provided in relation to need.
104
 Inequality in health care can be both 
horizontal and vertical. Vertical equality implies that individuals with different 
levels of need should have access to different amounts of health care; amounts 
that correspond to their needs. Horizontal equality implies that persons who have 
the same level of need should have access to the same amount of health care.
105
 
This thesis focuses on horizontal equality in health care use. 
Health care should be equal irrespective of age, gender, place of residence, 
functional capacity, ethnicity, religion, sexuality, education and other social 
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factors.
106
 This thesis focuses on inequality related to age and SEP (education). 
To study whether health care use matches need, it is important to measure a 
person’s actual need for health care. The best method for assessing need is the 
focus of much discussion in the field of health care inequality research.
107
 Need 
is most often assessed by using some measure of health status
108
 or by 
comparing patients with the same disease. 
In Sweden, socioeconomic inequality in health care use was small in the 1970s 
and 1980s
109
 but increased during the 1990s.
109, 110
 Since then, studies have 
found the socioeconomic differences in Sweden are of a similar magnitude to 
those in other high income countries.
17, 18, 101, 111
 The general finding in Sweden 
is that, in relation to need, the use of GP care is equal across social groups, 
whereas the use of specialised care tends to be higher among persons with high 
SEP.
112, 113
 The same pattern is found in many other high income countries. Most 
health care inequality studies do not specifically focus on older adults, but the 
results of most studies on health care inequality among older adults mirror the 
results of studies on younger age groups.
101, 114, 115
 
1.4.2 Prescribing in Sweden 
The vast majority of all drugs prescribed in Sweden are prescribed by 
physicians, although some nurses and dentists also have limited rights to 
prescribe.
62
 The number of drugs used by older adults has increased over time,
116
 
which is also reflected in an increase in drug expenditure in Sweden. Between 
the 1990s and early 2000s, drug expenditure increased by approximately 10% 
annually, but the increase has slowed down since 2005.
117, 118
 The increase in 
drug expenditure was driven by both newer expensive drugs and increased drug 
use for chronic conditions.
117
 In 2004, drug costs represented 12% of the total 
health care expenditure in Sweden. 
Patients’ expenditures on prescription drugs are largely reimbursed in Sweden. 
The Dental and Pharmaceutical Benefits Agency (‘Tandvårds- och 
läkemedelsförmånsverket [TLV]’) is a governmental agency responsible for 
deciding which drugs are subsidised by the state. The TLV decides which drugs  
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to include in the high-cost threshold on the basis of medical, humanitarian and 
financial considerations. Drugs included in the high-cost threshold are 
reimbursed from the state. The patient receives gradual reimbursements, 
calculated on a yearly basis, and the patient is fully reimbursed (100%) when the 
yearly expenses exceed 2200 Swedish Crowns (SEK) (Figure 4).
119
 The 
maximum yearly individual expenditure was increased from 1800 SEK to 2200 
SEK in 2012.
119
 
 
Figure 4. Reimbursement scheme (high-cost threshold) for prescribed drugs on a 
12-months basis in Sweden (Costs in Swedish crowns [SEK]). Source: FASS.se.  
1.4.3 What explains inequality in use of health care and drugs? 
The causes of inequality in health care and drug use are far from understood but 
are likely to be complex and multifaceted.
107
 Models of factors that affect access 
to health care have been developed. The models have been used to discuss where 
in the process of health care use inequality might arise. However, these models 
have rarely taken prescribing of drugs into account. 
1.4.3.1 The behavioural model of health services use 
The most influential model of access to health care is the Behavioural Model of 
Health Services Use, which has been gradually developed since the 1960s (for 
overviews, see Andersen 1995
120
 and Andersen 2008
121
). The behavioural model 
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is a conceptual framework that broadly outlines three sets of predictive factors 
that influence care use: need factors, enabling factors and predisposing factors. 
Each factor can further be divided into individual or contextual dimensions. The 
model defines access to health care as actual health care use. The model can be 
used for predicting use of health care, promoting social justice (equal care) and 
investigating effectiveness.
122
 
Individual-level need factors are thought to affect how people respond to their 
general health, illness and symptoms. In other words, individual factors influence 
how people perceive their needs. In turn, perception of needs influences care-
seeking behaviors. Contextual need factors involve the physical environment of 
the individual. As an example, the proximity of health care services in a 
neighbourhood can influence health-care seeking among individuals living in the 
neighbourhood.
122
 
At the individual level, enabling factors include the financial means to pay for 
health care services, access to transportation and having time to visit health care 
services. At the contextual level, enabling factors can include health policies that 
promote health and utilisation of health care services.
120, 122
 
Predisposing factors include individual traits such as education, occupation and 
social networks that might affect a person’s ability to handle health problems and 
command resources. Contextual predisposing factors are related to the 
composition of the community. For instance, if people in the individual’s 
community are generally well educated or if most are old, it can affect the degree 
of services in the area and the health beliefs of those living in the community.
122
  
1.4.3.2 The behavioural model of prescribing 
Nordin et al.
24
 have extended the behavioural model of health services use by 
proposing a model for the drug utilisation process: 
1. Demand for health care (response to illness) 
2. Demand meets supply (i.e., the patient meets an available and affordable 
doctor who can prescribe the drug) 
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3. Health care production (the doctor writes out the prescription on the basis 
of medical and possibly other considerations) 
4. Dispensing of the drug (the patient collects the drug if the patient can 
afford/have access to a pharmacy/adheres to the treatment) 
5. Consumption of the drug (the patient consumes the drug if s/he adheres 
to the treatment) 
In Nordin et al.’s extended model,24 the same factors (need, enabling and 
predisposing) are thought to influence access to pharmaceutical care, but the 
researchers have add steps not explicitly discussed in the behavioural model of 
health services use; namely the steps from the prescribing to the consumption of 
drugs (steps 3–5). A similar model has also been proposed by Weitoft et al. 
2008
123
 and is depicted below (Figure 5). The figure illustrates a health-care use 
chain in which socioeconomic factors can have an influence at different points in 
the process. 
 
Figure 5. Conceptual framework of sociodemographic influences on drug use. 
Source: Weitoft et al. 2008.
123
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The models provide guidance as to where inequality can arise in the complex 
process of health-care seeking and provision of care. The models incorporate 
multiple levels and factors that can influence the delivery of care at many 
different points in the process. However, the models are difficult to test as they 
are all-encompassing and provide little information about the directionality of 
influences between and among the different levels and factors. 
1.4.3.3 Other mechanisms 
A range of mechanisms have been suggested to explain inequalities in drug use. 
Most suggestions come from qualitative work because quantitative studies often 
provide little information on underlying pathways. A notable example of a 
qualitative study that highlights the mechanisms linking SES with differences in 
treatment is Lutfey & Freese 2005.
124
 They set out to further develop the 
fundamental cause theory of health inequalities by using in-depth ethnographic 
data to study the explicit mechanisms that lead to differences in care. By 
comparing the routine care at two diabetes clinics (one with predominantly white 
and middle/upper class patients, the other with predominately black/Hispanic 
and working class patients), Lutfey and Freese found a large number of potential 
mechanisms likely to produce and reproduce the endurable relationship between 
SES and health care use/outcomes. They found mechanisms in many aspects of 
care that are likely to maintain the unequal use and outcomes of care, even as 
new treatments are developed and enter the market. The proposed mechanisms 
were visible in the organisation of clinics, external barriers to seeking care, 
differences in patient motivation (and the apprehension of motivation by the 
physicians) and in cognitive ability. Many other mechanisms have also been 
proposed in the literature. Some of the proposed mechanisms are discussed 
below; the discussion covers mechanisms at the individual level, those that 
involve patient-physician interaction, and those at the societal or system level. 
1.4.3.4 Individual level 
Possible individual-level mechanisms range from patients’ preferences to 
financial means. One set of suggested pathways is mainly cognitive. It includes 
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factors such as socioeconomic differences in knowledge
125
, health literacy
99
 and 
health beliefs.
126
 Such explanations propose that individuals with lower SEP 
have less health-related knowledge, which in turn leads to poorer access and 
utilisation of health care services. Another set of explanations predominantly 
highlights patients’ preferences and attitudes; these explanations often suggest 
that individuals with low SEP have attitudes that are less health-enhancing, and 
that this is linked to an inadequate use of health care.
127, 128
 
Other explanations relate to the physical environment. These suggest that 
differences are due to geographical distances and transportation.
129
 Still other 
research suggests that financial resources are a pathway, both through 
differences in the ability to pay for health services and differences in competing 
demands from work.
130-132
 
1.4.3.5 Physician-patient interaction 
The patient-physician interaction has been studied and discussed for a long time 
(for an overview, see Heritage et al. 2006
133
). Studies propose a number of 
mechanisms as to how the physicians’ and patients’ perceptions and behaviours 
interrelate and influence differences in treatment.
134
 The provider contribution to 
differences in treatment often draws on social cognition research and highlights 
the risk that physicians may stereotype specific subgroups. Stereotyping can 
entail ascribing negative characteristics and behaviours to subgroups, leading to 
preconceived ideas that can influence the choice of treatment.
135, 136
 Other 
research has emphasised the role of patients’ expectations of and demands for 
care, which can influence physicians' decisions about whether or not to treat.
137, 
138
 This research suggests that the expectations and demands are most likely 
related to SEP.  
Furthermore, research has shown that physicians are influenced by therapeutic 
traditions. For instance, physicians who work at the same health care centre have 
similar prescribing patterns,
139
 and physicians working at private clinics 
sometimes prescribe differently than those who work at public clinics.
139, 140
 
Private clinics are more common in areas with a high concentration of people 
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with high SEP, which can translate into socioeconomic differences at a national 
level.
141
 
1.4.3.6 Societal level 
More general and upstream factors such as the organisation and financing of the 
health care system also have consequences for the way socioeconomic 
differences affect health care and drug treatment. The Swedish health system, 
which has universal coverage, is probably better at equalising differences in 
health care use than systems that use private health insurance.
142
 However, even 
in Sweden, reimbursement schemes that affect out-of-pocket expenses are likely 
to influence different socioeconomic groups in different ways.
130
 For instance, 
when prices increase, persons with lower SEP are more likely to refrain from 
collecting drugs. 
1.4.4 Socioeconomic differences and drug prescribing 
Sweden was among the first countries to produce statistics on drug prescribing. 
First, Sweden gathered wholesale statistics from Apoteket AB, Sweden’s 
government-owned national pharmaceutical retailer, which formerly had a 
monopoly on prescription drug sales. These statistics could be used to assess 
prescribing trends and regional/international variations.
143
 Second, data were 
gathered by recording individuals’ outpatient drug use in two regional settings: 
the county of Jämtland
144
 and the municipality of Tierp
145
 starting in the early 
1970s. In 2005, the Swedish Prescribed Drug Register (SPDR) was introduced; 
this register includes individual-level prescription data for all people in 
Sweden.
146, 147
 
One of the first studies to focus on socioeconomic differences in drug use in 
Sweden was published 1988 and based on the Tierp study.
131
 The authors found 
small differences: people of lower social class used more psychotropics, and this 
difference was found both in people of working age and those who were 
retired.
131
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A number of studies have also examined the association between indicators of 
SEP and the number of drugs used (e.g., polypharmacy) among older adults or in 
the general population, in Sweden and elsewhere.
19, 116, 148-153
 With a few 
exceptions,
150
 these studies found that people with low levels of education used 
more drugs. However, as some of the authors have noted, the more extensive use 
of drugs reported among people with low SEP likely reflects the differences in 
health between social groups.
152
 
Some of the studies that analyse the association between SEP and polypharmacy 
have also included other measures of drug use, such as quality indicators.
19, 116, 
149
 Haider et al.
19, 116
 found that low SEP was associated with more potentially 
inappropriate drug-drug interactions and inappropriate use of three or more 
psychotropics among older adults. The socioeconomic differences in drug-drug 
interactions  are partially expected since drug-drug interactions are highly 
correlated to the number of drugs used.
154
 Odubanjo et al.
149
 also found that 
relatively deprived older adults were more likely to receive potentially harmful 
drugs and were more likely to receive treatments that were not evidence-based. 
An overview of studies of socioeconomic differences in drug use that have 
focused specifically on older adults (aged 65+ years) can be found in Table 1. 
A nationwide register-based study, by Ringbäck Weitoft et al.,
123
 reported that in 
the general population of Sweden, the socioeconomic differences in prescribing 
followed the social gradient in disease prevalence for most drug types. Among 
the exceptions were antibiotics, hormone replacement therapies, migraine 
medications and dementia drugs. The authors concluded that more studies are 
needed in which data on individuals’ diseases are available, as this will make it 
possible to differentiate between socioeconomic differences in need and 
prescribing.
123
 
A number of disease-specific studies have also been published in which 
socioeconomic differences in drug use have been found for patients with the 
same conditions. Examples include studies on osteoporosis,
22
 epilepsy,
155
 and 
acute myocardial infarction.
20, 156
 In all these studies, lower SEP was linked to 
less optimal drug treatment. 
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Inequality in the cost of drugs has also been found between socioeconomic 
groups. In a study of a nationally representative sample of Swedes, researchers 
found that women with a higher level of education were prescribed more 
expensive drugs than women with a lower level of education, for general drug 
use. No education-based differences were found in men, and no income-based 
differences were found in either women or men.
24
 Further, for specific drugs, the 
socioeconomic-based difference was greater when the drug was prescribed for 
diseases that are not severe (e.g., sildenafil for erectile dysfunction). A register-
based study of people in Stockholm County found that public expenditure on 
health care in the last year of life was larger for persons with higher income.
157
 
One explanation for the difference in costs for drugs might be that more affluent 
persons are prescribed more brand-name drugs, as studies of older Canadians
158
 
and of statin users in the Swedish region of Skåne
140
 have found. 
In Sweden, the cost of drugs is not fully covered by public money; patients must 
also pay a portion of the cost of prescription drugs they collect at pharmacies. 
When a patient does not collect a prescription, it is called primary non-adherence 
or non-initiation.
159
 In Sweden, more deprived persons are more likely to be 
primary non-adherent, and the relative difference between socioeconomic groups 
increases at older ages.
160
 However, it is not clear whether this is because of 
poorer financial resources or lower levels of trust in the health care system 
among more deprived persons.
160
 One study has found that persons with lower 
education or lower income are more sensitive to increases in the price of drugs: 
if the patients’ user fees would increase, then primary non-adherence would 
increase more in persons with low SEP.
130
 However, in this hypothetical 
situation, the researchers also found that price sensitivity decreased with age. 
Thus, older adults were less likely than younger adults to change their primary 
adherence if patient fees increased.
130
 In a nationally representative survey of 
persons aged 77 years or older in Sweden, as few as 1% of respondents reported 
having refrained from collecting drugs for financial reasons.
161
 
A number of studies have also examined how area effects and individual 
socioeconomic conditions affect different measures of drug use. These studies 
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found that people with low SEP are more likely to receive cheaper and older 
lipid-lowering agents
139, 140
, have lower adherence to antihypertensives
162
 and to 
have lower general primary adherence
163
 over and above the studied area effects. 
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Table 1. Overview of studies investigating socioeconomic differences in drug use among persons aged 65 years or 
older. 
Author, 
year 
Participants Indicator of SEP Measure of drug use Main findings 
Mamdani et 
al. 2002
158
 
N=128,314, age ≥65, 
residents of Ontario (Canada) 
initiating specific therapies  1 
January 1998 through 31 
December 1999 
Neighbourhood 
income 
Generic vs. brand name agents Increases in neighbourhood median 
income levels were associated with 
the selection of newer brand-name 
drugs  
Odubanjo 
et al. 
2004
149
 
N= 95,055, age ≥70, in the 
Eastern region in Ireland and 
included in the General 
Medical Services Scheme  
Means tested group 
(deprived) vs. non-
means tested group 
(affluent) 
(1) Number of drugs 
(2) Potentially harmful 
prescribing 
(3) Evidence-based prescribing 
The non-means tested groups used 
fewer drugs, used fewer potentially 
harmful drugs and were more likely to 
have evidence-based treatments  
Haider et 
al. 2007
116
 
N=512 (year 1992) + 561 
(year 2002), age ≥77, 
nationally representative 
sample of Swedes 
Education (1) Drug user 
(2) Number of drugs 
(3) Drug-drug interactions 
Highly educated persons were less 
likely to be drug users, used fewer 
drugs and were less likely to have a 
drug-drug interaction. The education-
based difference increased from 1992 
to 2002 in women 
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Haider et 
al. 2008
23
 
N=626,258, age 75–89 who 
filled at least one drug 
prescription from August 
through October 2005; data 
from the SPDR 
Education Newly marketed drugs Persons with a higher level of 
education were more likely to use 
newly marketed drugs then persons 
with low education 
Haider et 
al. 2008
148
 
N=621 (year 2002), age ≥77, 
nationally representative 
sample of people in Sweden 
Education, 
occupation and 
income 
Polypharmacy (≥5 drugs) Low education was the only SEP 
indicator associated with more 
polypharmacy. The association 
disappeared after adjustment for co-
morbidity, marital status and living 
situation 
Haider et 
al. 2009
19
 
N=626,258, age 75–89 who 
filled at least one drug 
prescription from August 
through October 2005; data 
from the SPDR 
Education (1) Polypharmacy (≥5 drugs) 
(2) Excessive polypharmacy 
(≥10 drugs)  
(3) Potential inappropriate drug 
use 
Highly educated persons were less 
likely to have polypharmacy, 
excessive polypharmacy and to use 
three or more psychotropic drugs 
Lesén et al. 
2010
164
 
N=384,712, age ≥75 who 
filled at least one psychotropic 
drug prescription during 2006; 
data from the SPDR 
Income (1) Three or more 
psychotropics 
(2) Potentially inappropriate 
psychotropic drug use  
Persons with higher income were less 
likely to use three or more 
psychotropics and to have a 
potentially inappropriate psychotropic 
drug use 
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2 AIMS 
2.1 GENERAL AIM 
To investigate whether drug treatment is unequally distributed among older 
adults on the basis of age and SEP. 
2.2 SPECIFIC AIMS 
2.2.1 Study I 
To investigate and describe drug use among people aged 80–89, 90–99 and 100+ 
years with respect to number of drugs used and the most commonly used drug 
classes. 
2.2.2 Study II 
To investigate educational differences in osteoporosis drug treatment before 
osteoporosis-related fracture (primary prevention) and after osteoporosis-related 
fracture (secondary prevention). 
2.2.3 Study III 
To investigate educational differences in treatment with antipsychotics in older 
adults with dementia and in the general population. 
2.2.4 Study IV 
To investigate educational differences in access to specialised prescribing 
(geriatricians and psychiatrists) among older adults who use psychotropics. 
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3 MATERIAL AND METHODS 
The Nordic countries (Sweden, Norway, Finland and Denmark) are the only 
countries in Europe with the ability to link pharmaceutical registers to other 
nationwide databases using personal identification numbers.
165
 Thus, it is 
possible to collect drug data that are highly representative of the general 
population in Sweden (about 9.7 million inhabitants) and can be linked to data in 
other registers and data sources.  
3.1 DATA SOURCES 
3.1.1 The Swedish Prescribed Drug Register (SPDR) 
The SPDR was introduced in its current individual-based form in 2005. The 
register contains information on all prescribed drugs dispensed at Swedish 
pharmacies; in other words, all drugs picked up by the people for whom they 
were prescribed (or the legal guardians of these people). The register, which also 
includes information on multi-dose drug dispensing (‘ApoDos’), is one of the 
largest pharmacoepidemiological databases in the world.
146
 Only prescribed 
drugs that are actually collected are recorded in the register. Hence, if a drug is 
prescribed but not collected, it is not registered in the SPDR. In this thesis, the 
terms ‘dispensed’, ‘prescribed’, and ‘collected’ are used interchangeably to 
denote prescribed drugs that were also collected from the pharmacy. For each 
such drug, information on package size, drug name, dosage of the drug, strength 
of the preparation and more is recorded in the register. 
We investigated drug use at two points in time, July to September 2009 (Study I) 
and July to October 2005 (Study II-IV). Our study windows of 3 and 4 months 
should include all regularly used drugs because the maximum amount of a drug 
that may be dispensed is a 3-month supply. 
In Study I, we were interested in overall drug treatment and did not focus on a 
specific type of drug. We therefore analysed the concurrent use of drugs on a 
specific day (30 September, the last day of the study period) to avoid 
overestimating current drug treatment. A one-day point prevalence was 
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constructed using information about the date of dispensing, amount of drugs 
dispensed and the dosage of each dispensed drug to calculate if the drug was 
used on the 30 September. When dosage was incomplete or missing (8.7%), we 
based our calculations on the defined daily dose (DDD). The DDD is the 
assumed average dose per day of a drug used for its main indication in adults, as 
recommended by the World Health Organization (WHO).
166
 If a person was 
dispensed the same drug in different doses this was counted as one dispensed 
drug. 
In studies II through IV, we wanted to investigate exposure to certain drug 
classes. Therefore, drug use was calculated for a 4-month time window rather 
than for one specific day. This method probably overestimated the overall 
number of concurrently used drugs. 
Drugs administered in hospitals, over-the-counter drugs (OTC-drugs), and drugs 
supplied from store rooms in nursing homes are not included in the SPDR. This 
probably led to an underestimation of the number of drugs used.  
3.1.1.1 Drug information 
Detailed information on patients’ drug use is included in the SPDR: drug name 
and strength, date of dispensing, package size and doses.  
3.1.1.2 Patient characteristics 
Further, some key characteristics of the patient is also included, such as age, 
gender and place of residence.  
3.1.1.3 Physician characteristics 
It is not possible to identify individual physicians in the SPDR. However, for 
each dispensed drug, some of the prescribing physician’s characteristics are 
included, such as prescriber profession (physician, nurse or dentist), workplace 
(e.g., hospital or health care centre) and physician specialty (e.g., geriatrician or 
psychiatrist). 
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3.1.2 The Swedish Educational Register (SER) 
The SER contains information about the highest educational level achieved by 
most Swedish citizens aged 74 years or younger (the upper age limit was 
removed in 2008). Educational attainment data were collected from the Swedish 
censuses (‘Folk- och Bostadsräkningarna’) and then continuously updated with 
information from Swedish schools and universities. The registered level of 
educational attainment for most Swedish older adults is from the Swedish census 
in 1990. The studies that include level of educational attainment in this thesis use 
data from the SPDR in 2005; thus, we could use the educational information 
from 1990 census to study the educational attainment for people up to the age of 
89 years (studies II through IV).
167
 
The SER combines the highest attained level of schooling and years in school. 
Highest attained level refers to compulsory, upper secondary or university 
education. The years of education are the number of years at each attainment 
level.
167
  
3.1.3 The Swedish Patient Register (SPR) 
The SNPR was introduced on a local basis in the 1960s and was then gradually 
expanded to cover all of Sweden. Since 1987, the register has included 
information on all hospital discharges across the country. All surgical procedures 
(including day surgery) have been included since 1997, and all outpatient visits 
to specialists since 2001.
168
 
This thesis mainly uses discharge diagnosis information on main diagnosis and 
secondary diagnoses (studies II through III). The SPR also include other 
variables, such as health care setting. A validation of the register found that 99% 
of discharges from both somatic and psychiatric hospital care were recorded.
169
  
3.1.4 The Swedish Social Services Register (SSSR) 
The SSSR was initiated in 2007 and includes information on social services for 
people aged 65 years and older administered by the municipalities in Sweden 
(e.g., home help and institutional care) . The register includes individual-level 
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information based on decisions by needs assessors (‘biståndsbedömare’). We 
obtained information on institutional care for 30 June 2008 (Study I).
170
 
3.2 OUTCOME MEASURES AND EXPLANATORY VARIABLES 
3.2.1 Outcome measures 
Drug use is the outcome in all the studies included in this thesis. As 
recommended by WHO, drugs were classified using the Anatomical Therapeutic 
Chemical (ATC) system.
166
 For an overview of the studies included in the thesis, 
see Table 2. 
3.2.1.1 Drug use in centenarians (Study I) 
We compared drug use in centenarians to drug use in octogenarians and 
nonagenarians in Sweden. We compared the number of drugs and the prevalence 
of the 16 most commonly used drug groups. 
3.2.1.2 Osteoporosis drugs (Study II) 
We analysed use of any osteoporosis drug and the use of three different types of 
osteoporosis drugs: calcium/vitamin D combinations (A12AX), bisphosphonates 
(M05BA and M05BB) and SERMs (G03X; only in women). Use of each type of 
osteoporosis drug was analysed separately. 
3.2.1.3 Antipsychotics in persons with and without dementia (Study III) 
We analysed use of any antipsychotic drug (N05A) and the use of two main 
types of antipsychotics: second-generation antipsychotics (N05AE04, 
N05AH02, N05AH03, N05AH04, N05AAX08 and N05AX08) and first-
generation antipsychotics (all other N05A drugs). Use of the two main types of 
antipsychotics was analysed separately. 
3.2.1.4 Specialist psychotropic prescribing (Study IV) 
In psychotropic drug users, we analysed whether psychotropics were prescribed 
by a ‘geriatrician’, ‘psychiatrist’ or ‘other specialist’ (mainly GPs). We analysed 
specialist psychotropic prescribing of four types of psychotropics: antipsychotics 
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(N05A), anxiolytics (N05B), hypnotic/sedatives (N05C) and antidepressants 
(N06A). 
3.2.2 Explanatory variables 
3.2.2.1 Educational level 
Educational level was classified on the basis of years of education and 
educational attainment: low educational level (compulsory school; that is, less 
than 9 years of education), medium educational level (upper secondary 
schooling, including ‘realskola’; that is, 9 to 12 years of education) and high 
educational level (a university education; that is, more than 12 years of 
education) (studies II through IV). 
3.2.2.2 Age 
In Study I, age was classified into 80–89 years (octogenarians), 90–99 years 
(nonagenarians) and 100+ (centenarians). 
In studies II and III, age was classified as 75–79 years, 80–84 years and 85–89 
years. 
In Study IV, age was included as a continuous variable. 
3.2.2.3 Gender 
Gender was included as a dummy variable in studies I, III and IV. In Study II (of 
osteoporosis drug use), all analyses were performed separately for each sex. 
3.2.2.4 Co-morbidities 
In studies I through IV, we used number of drugs as a proxy measure of overall 
co-morbidity, as suggested by Schneeweiss et al.
171, 172
 However, given that the 
number of drugs a person uses is a crude assessment of co-morbidity, some 
residual confounding is inevitable.
172
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3.2.2.5 Dementia status 
In Study III, dementia status was measured with diagnosis of dementia in the 
SNPR or use of dementia drugs (N06D) in the SPDR. In Study IV, only 
dementia drug use noted in the SPDR was used to assess dementia status. 
3.2.2.6 Type of housing 
People were classified as community-dwelling (living at home) or living in an 
institution (e.g. in a nursing home or sheltered accommodation). Information on 
type of housing was obtained from the SSSR.
173
 
3.2.2.7 Geographical areas 
In Study IV, geographical place of residence was classified as a metropolitan or 
a non-metropolitan area. The classification was made on the basis of county of 
residence: Stockholm, Gothenburg and the Malmö region were coded as 
metropolitan.  
In Study III, we calculated corrected standard errors to account for unobserved 
homogeneity at the municipality level (n=290). 
In Study III, we included the Swedish counties (n=21) as dummy variables to 
adjust for geographical differences. 
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Table 2. Overview of the data sources and variables used in this thesis. 
 Data 
source* 
Outcome Main 
independent 
variable 
Other covariates Stratification 
variables 
Exclusion 
Study I 
 
SPDR  
SSSR  
 
Number of drugs 
 
16 most commonly 
used drugs 
Age  
(80–89, 90–99, 
100+) 
Gender 
Living situation 
Number of other drugs (co-
morbidity) 
None Missing data 
Study II 
 
SPDR 
SER  
SPR 
 
Use of osteoporosis 
drugs 
 
Different types of 
osteoporosis drugs 
Education  
(<9 years, 9–12 
years, >12 years) 
Age 
(75–79, 80–84, 85–89 years) 
Fracture diagnosis 
Number of other drugs 
Gender 
Fracture 
Missing data 
Study III 
 
SPDR 
SPR 
 
Use of antipsychotic 
drugs 
 
Different types of 
antipsychotic drugs 
Education 
 (<9 years, 9–12 
years, >12 years) 
Gender 
Age  
(75–79, 80–84, 85–89 years) 
Dementia diagnosis 
Dementia drug use 
Number of other drugs 
County 
Dementia 
status 
Missing data 
 
Study IV 
 
SPDR 
 
Specialist-prescribed 
psychotropic drugs  
Education 
 (<9 years, 9–12 
years, >12 years) 
Gender 
Age (in years) 
Metropolitan area 
Dementia drug use 
Number of other drugs 
None Missing data. 
Diagnosis of 
intellectual disability, 
schizophrenia, or 
bipolar disorder 
*SPDR, Swedish Prescribed Drug Register; SSSR, Swedish Social Service Register; SER, Swedish Educational Register; SPR, Swedish Patient 
Register
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3.3 STATISTICAL ANALYSES 
The analyses were performed with SPSS, version 17 (SPSS Inc., Chicago, IL, 
USA) and STATA 11. 
3.3.1 Study I 
We used logistic regression analysis, unadjusted and adjusted, to investigate the 
association between age and use of the 16 most commonly used drugs among 
centenarians compared to nonagenarians and octogenarians (reference category). 
In the unadjusted model, only the age groups were included as independent 
variables. In the adjusted model, gender, type of housing and number of other 
drugs (a proxy for overall co-morbidity) were also included as independent 
variables. 
3.3.2 Study II 
All analyses were performed separately for women and men. The analysis was 
performed in two steps. First, unadjusted (only level of education) and adjusted 
(including age group, fracture diagnosis and number of other drugs) logistic 
regressions analysis was performed in the total study sample to investigate the 
association between education and use of osteoporosis drugs. Second, we 
repeated the analysis for the subsample of persons with osteoporosis-related 
fractures. 
3.3.3 Study III 
The analysis was performed in two steps. First, unadjusted (only level of 
education) and adjusted (including age group, sex, dementia diagnosis, dementia 
drug use, county and number of other drugs) logistic regression analysis was 
performed in the total study sample to investigate the association between 
education and use of antipsychotic drugs. Second, we repeated the analysis for 
the subsample of persons with a dementia diagnosis and/or who had a 
prescription for one or more dementia drug. 
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3.3.4 Study IV  
Multinomial regression analysis with three outcomes (geriatrician, psychiatrist, 
or other specialist [the latter was the reference category and consisted mainly of 
GPs]) was performed to investigate the association between patients’ level of 
education and specialised prescribing of psychotropics. The analyses were 
performed for each of the four types of psychotropics (antipsychotics, 
anxiolytics, hypnotic/sedatives and antidepressants) separately. Model I was the 
unadjusted model; only education was included as an independent variable. 
Model II was adjusted for age, sex, dementia, and number of other drugs. Model 
III was further adjusted for metropolitan/non-metropolitan place of residence. 
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4 ETHICAL CONSIDERATIONS 
All studies used anonymised register-based data. The Swedish National Board of 
Health and Welfare linked the data in the various registered and removed the 
personal identification numbers. The studies were approved by the ethical review 
board in Stockholm (dnr 2006/948-31; 2009/477-31/3).
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5 MAIN RESULTS 
5.1 STUDY I 
Little is known about drug use in extreme old age. Thus, the objective of Study I 
was to investigate drug use among centenarians and compare it to drug use 
among nonagenarians and octogenarians. On average, centenarians used a 
similar number of drugs (5.1) to nonagenarians (5.7) and octogenarians (5.3). 
The proportion of persons living in an institution increased with age, from 11% 
of octogenarians to 59% of centenarians. Individuals who lived in institutions 
used more drugs than home-dwelling persons, and this difference was more 
pronounced in the younger age groups. Among centenarians, the most 
commonly used drug classes were cardiovascular drugs, psychotropics and pain 
killers. 
Using logistic regression, we further investigated the association between age 
groups and use of different types of drugs. Centenarians were more likely to use 
psychotropics (hypnotic sedatives, antidepressants and anxiolytics) and pain 
killers (minor analgesics and opioids) than octogenarians in the unadjusted 
analysis. The results were confirmed in the logistic regression analysis (with 
adjustment for sex, living situation and number of other drugs) for all drug types 
except antidepressants.  
Centenarians were more likely to use diuretics (high-ceiling diuretics and 
potassium-sparing diuretics) than octogenarians in both the unadjusted and 
adjusted models. However, centenarians were less likely to use other types of 
cardiovascular drugs (antithrombotic agents, beta blockers and ACE inhibitors) 
than octogenarians in the unadjusted and adjusted analysis.  
Gender differences in centenarians’ drug use were in general small, except for 
use of antidepressants, which was more commonly used among women.  
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5.2 STUDY II 
Results of smaller and more selected studies suggest that there are differences in 
osteoporosis drug use by socioeconomic position. Thus, our aim was to study 
SEP differences in osteoporosis drug use in a large data set with nationwide 
coverage. 
In the total study population, 11.5% of the women and 5.0% of the men had 
sustained an osteoporotic fracture. Of the women, 15.2% used calcium/vitamin 
D combinations, 7.3% used bisphosphonates and 0.4% used SERMs. Of the 
men, 3.3% used calcium/vitamin D combinations and 1.1% used 
bisphosphonates. Of the persons with a previous fracture, only 32% of women 
and 10% of men used an osteoporosis drug (Figure 6). 
 
Figure 6. The proportion of women and men who used any osteoporosis drug in 
the total study sample and in the fracture subgroup by educational level, Sweden 
2005. 
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We found that the proportion of people who used osteoporosis drugs increased 
with increasing educational level in both women and men. In the subgroup of 
persons who had sustained a fracture, the use of osteoporosis drug treatment was 
higher. However, also among those who had sustained a fracture, people with a 
high level of education used more osteoporosis drugs. 
Further analysis with logistic regression confirmed that a high level of education 
was associated with osteoporosis drug use in the total sample in both women and 
men after adjustment for age, osteoporotic fractures and number of other drugs. 
The odds ratio (OR) was higher for bisphosphonates and SERMs than for 
calcium/vitamin D combinations. In the subgroup analysis of persons with an 
earlier fracture, a high level of education was still statistically significantly 
related to osteoporosis drug use in women. Such a tendency was also found in 
men (OR higher than 1), although the differences were not statistically 
significant. 
In the total sample, older age was positively associated with the use of 
calcium/vitamin D combinations but negatively associated with use of the more 
potent drugs (bisphosphonates and SERMs). Furthermore, in the fracture 
subsample, older age was negatively associated with all osteoporosis drug use 
among women and with use of bisphosphonates among men. 
5.3 STUDY III 
Antipsychotic drugs are commonly used to treat BPSD in persons with dementia. 
Our aim was to study differences in antipsychotic drug use among persons with 
or without dementia by educational level. In the total study population, about 5% 
used a dementia drug and/or had a dementia diagnosis. Of the persons with 
dementia, 21% were treated with antipsychotics, whereas 4% of the total study 
population were treated with such drugs. First and second generation 
antipsychotics were used to a similar extent among the total study population, 
whereas second-generation antipsychotics were more common in persons with 
dementia. 
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The proportion of persons who used antipsychotics was higher among those with 
a low level of education, both in the total study population and in the dementia 
subsample. This was true of both first and second generation antipsychotics. 
In the total study population, lower educational level was also associated with 
higher use of antipsychotic drugs in the logistic regression analysis (after 
adjustment for age, dementia drug use, dementia diagnosis and number of other 
drugs). A diagnosis of dementia in the patient register yielded a higher adjusted 
OR (OR low vs. high 7.4; 95% confidence interval [CI] 7.1–7.7) of using 
antipsychotic drugs than did use of a dementia drug (adjusted OR low vs. high 
2.4; 95% CI 2.3–2.6). 
Higher OR of use of antipsychotic drugs was also found among those with a low 
level of education in the subsample of persons with dementia after adjustment 
for age, sex and number of drugs. In all the analyses, the differences by 
educational level were found for any use of antipsychotics, for use of first-
generation antipsychotics and for use of second generation antipsychotics. 
Use of antipsychotics increased with age both in the total study population and in 
the dementia subsample.  
5.4 STUDY IV 
The majority of prescriptions for psychotropics for older adults in Sweden are 
written by GPs. We investigated whether there were educational differences in 
the access to specialist prescribing (by geriatricians or psychiatrists) among older 
psychotropic drug users. In the study population of psychotropic drug users, the 
majority (87%) used only one psychotropic, 9% used two types, 4% used three 
types and 1% used all four types of psychotropics. The vast majority of 
psychotropic drug users had been prescribed their psychotropics by a physician 
from the category ‘other specialists’; 95% of these other specialists were 
specialists in family medicine (GPs). Only 9% received at least one prescription 
for a psychotropic from a geriatrician; 4%, from a psychiatrist; and less than 1%, 
from both a geriatrician and a psychiatrist. Furthermore, GPs prescribed the 
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majority of all types of psychotropic drugs; however, they prescribed a larger 
proportion of hypnotic/sedatives (83%) than antipsychotics (70%). 
For all psychotropic drug types, the proportion of psychotropics prescribed by 
GPs was higher for persons with a low level of education. The unadjusted 
multinomial regression models confirmed that high education was associated 
with more access to geriatrician and psychiatrist prescribing. However, when we 
adjusted for place of residence (Model III), the association between higher 
education and geriatrician prescribing became non-significant, whereas the 
association between higher education and psychiatrist prescribing persisted. 
Furthermore, increasing age was positively associated with obtaining a 
prescription from a geriatrician and negatively associated with obtaining a 
prescription from a psychiatrist.
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6 DISCUSSION 
6.1 MAIN FINDINGS 
The results of this thesis give support to the hypothesis that drug use among 
older adults varies by SEP. Thus, educational inequalities in drug use seem to 
persist to older ages and exist for some of the most prevalent diseases and 
conditions among older adults. 
Furthermore, there also seem to be age differences in drug treatment. In general, 
older age was associated with less optimal drug use. 
6.2 EDUCATIONAL DIFFERENCES IN DRUG USE 
It is well-known that health and disease is socially patterned; this finding has 
been consistently found across time and geography.
15, 73-75
 The mechanisms 
linking poor social circumstances to poor health are many; poorer access to 
health care among less privileged persons in society is among the suggested 
mechanisms.
174
 To receive drug treatment is often the end point in the health 
care chain.
24, 123
 Additionally, inequality in drug treatment has been used as an 
example of how more advantaged people can utilise their flexible resources to 
gain better health in an ever-changing landscape of risk factors, resources and 
diseases.
92
 In this thesis, SEP is only measured as level of education. Use of 
complementary indicators of SEP would have allowed a more refined analysis. 
However, education is often a prerequisite for higher occupational positions and 
higher income and is therefore highly related to other socioeconomic 
indicators.
94
 Socioeconomic differences in drug treatment are not only unjust in 
themselves but can also point to inequalities in other areas of the health care 
system. Furthermore, suboptimal drug treatment can also lead to increased costs 
for the health care system because adverse drug reactions are a common cause of 
hospitalisation among older adults.
36
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6.2.1.1 Study II 
Previous studies have indicated that use of osteoporosis drugs may be unequal.
55, 
56
 The added value of our paper is the large unselected population and 
information on fracture status. By adding fracture status, we can confirm 
inequalities in both preventive treatment for osteoporosis and secondary 
prevention after a fracture (only statistically significant in women).  
Studies often find that socioeconomic disparities are larger for preventive 
treatments and screening; such findings could be explained by a higher level of 
health awareness among people with high SEP.
175
 After a fracture, most people 
in these age groups should be prescribed an osteoporosis drug.
176
 However, we 
find low treatment rates after fractures in general, particularly among men. The 
finding of educational differences among women even after a fracture is worth 
highlighting, since it suggests that differences in drug treatment by SEP also 
exist after being admitted to the hospital. Being admitted to the hospital should 
reduce the influence of patient behaviours and preferences for osteoporosis 
treatment. Furthermore, educational differences were larger for more newly 
marketed osteoporosis drugs, which gives support to earlier findings that show 
differences in the diffusion of new medical treatment and technology by 
patients’ educational level.23, 91 
6.2.1.2 Study III 
Antipsychotics are commonly used to treat BPSD.
65, 72
 During the past decade, 
efforts have been made to reduce the use of antipsychotic drugs among older 
adults with cognitive deficits.
71
 A study of a Canadian province, showed that 
older adults with dementia and low income were more likely to be treated with 
potentially inappropriate antipsychotic drugs than those with dementia and high 
income.
72
 We can confirm the finding from a Canadian province in a large-scale 
study conducted in another setting and with an alternative measure of SEP. In 
our study, we found higher use of antipsychotic drugs in persons with dementia 
than in cognitively intact older adults, which supports that antipsychotics are still 
widely used to treat BPSD. Moreover, persons with dementia and a low level of 
education were more likely to be prescribed an antipsychotic than were persons 
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with dementia and a high level of education. Research on whether the occurrence 
of BPSD varies by SEP is inconsistent.
177-179
 Thus, one possibility is that our 
finding reflects a higher burden of BPSD among persons with a lower level of 
education. Another possibility is that the prescription of antipsychotics is 
unequal. If our results reflect inequality in prescribing, it would suggest that the 
mechanism that links education to being prescribed antipsychotics to a relatively 
small extent goes through individual level characteristics. The ability to use 
cognitive resources to demand care is reduced in persons with dementia; thus, 
other factors such as having highly educated relatives (children) may be of 
importance.  
6.2.1.3 Study IV 
In Sweden, GPs prescribe the majority of psychotropics to older adults.
62
 In our 
study, we found that persons with a higher level of education were more likely to 
have access to specialised prescribing (by geriatricians and psychiatrists) than 
persons with a lower level of education. Studies have also found inequality in 
access to specialists for general health care use in older adults.
101, 114
 It is not 
clear from this study whether specialist prescribing leads to better prescribing 
and fewer adverse drug reactions for older adults with a high level of education. 
However, access to specialist prescribing (by specialist in the relevant field) 
could be an important pathway between patients’ levels of education and quality 
of prescribing. Further, the educational differences in access to specialised 
prescribing were partially explained by geographical variations. Living in a 
metropolitan area was highly associated with access, especially access to 
prescriptions from a geriatrician. This suggests that differences in drug use by 
educational level in many cases may be confounded by place of residence.  
6.3 AGE DIFFERENCES IN DRUG USE 
6.3.1.1 Study I 
In Study I, we found that the number of concurrently used drugs did not increase 
with age in the oldest segment of the population; i.e., centenarians did not use 
more drugs than nonagenarians. Thus, the common notion that drug use 
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increases with age does not seem to hold true in extreme old age. However, there 
were marked differences in the drug types most commonly used in centenarians 
and those most commonly used in nonagenarians and octogenarians. 
Anxiolytics, hypnotics/sedatives and painkillers were more often dispensed to 
centenarians than octogenarians. This might indicate that drug treatments are 
more palliative in character in centenarians than in younger age groups. 
Furthermore, cardiovascular drug therapy did not seem to follow guidelines to 
the same extent in centenarians as in nonagenarians and octogenarians. 
Centenarians used older types of cardiovascular drugs. This could reflect 
continued but not regularly re-evaluated use of specific drugs in centenarians, a 
disinclination to make changes in well-functioning drug therapy provided to the 
oldest old, or a tendency to focus on symptomatic rather than preventive 
cardiovascular drug treatment in centenarians.  
6.3.1.2 Study II 
In the total sample, older age was positively associated with receiving more 
calcium/vitamin D combinations. However, age was negatively associated with 
use of the more potent drugs; that is, bisphosphonates and SERMs. Further, 
when we focused only on people with a previous fracture, we found that 
increasing age was negatively associated with all osteoporosis drug use among 
women and with use of bisphosphonates among men. Because age is the 
strongest risk factor for osteoporosis, these results are surprising and seem to 
suggest that undertreatment of osteoporosis is common in older people.
45
 
Undertreatment of osteoporosis can lead to unnecessary fractures and 
subsequently mortality.
52, 180
 For bisphosphonates, an alternative explanation of 
the low treatment rate among the oldest old could be the difficulties in 
administering the drugs and uncertainty about the length of time patients should 
be treated with these drugs.
181
  
6.3.1.3 Study III 
Use of antipsychotics increased with age, but the association was not statistically 
significant for use of first-generation antipsychotics in the dementia subsample. 
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Antipsychotic drugs have been linked to severe side effects in older persons with 
dementia.
66-69
 Given the severe side effects, it is indeed important to try to reduce 
the use of antipsychotics, especially in older people, in whom high co-morbidity 
and lowered tolerance are to be expected. 
6.3.1.4 Study IV 
Age was positively associated with being prescribed psychotropics from a 
geriatrician but negatively associated with being prescribed by a psychiatrist. 
Thus, geriatricians seem to treat the patient group they are specialised in. The 
low rate of prescription of psychotropics by psychiatrists to older adults could 
reflect that mental health problems among older adults are a neglected problem 
and that older adults with such problems are mainly treated in primary care.
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6.3.1.5 Gender differences in Study I–IV 
Research has shown that there are gender differences in drug use in Sweden
183
, 
also among older adults.
34
 In the present thesis, most gender differences in 
centenarians’ drug use were found to be small (Study I). However, gender 
differences in osteoporosis drug use were relatively large; men were more often 
undertreated with osteoporosis drugs (Study II). Previous studies have also found 
low treatment rates for osteoporosis in men, and one explanation for these 
findings might be that osteoporosis is often perceived as a female disease.
54
  
There were no differences in antipsychotic drug use in women with dementia 
and men with dementia (Study III). This is somewhat surprising because men 
tend to display higher rates of aggressive behaviour when they experience 
BPSD.
184
 The gender differences in specialist prescribing of psychotropic drugs 
were small; women and men had similar chances of receiving a prescription of a 
psychotropic drug from either a geriatrician or a psychiatrist. 
6.4 LIMITATIONS 
A general limitation of this thesis is that only register data were analysed. A data 
source with more comprehensive information would have made it possible to 
explore potential confounders and underlying mechanisms in greater detail. On 
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the other hand, register data have the advantage of covering very large and 
unselected populations with high statistical precision. 
6.4.1 Selection bias 
In epidemiological studies, selection bias can arise if the selection of individuals 
into a study is systematically biased. The most common form of selection bias is 
that the non-response group differs systematically from the response group.
185
 In 
studies of older adults, non-response groups tend to have more health problems 
and lower cognitive abilities than response groups.
186
 Additionally, the oldest 
segment of the population tends to be underrepresented in pharmacy-based 
interview studies of drug use, since such people are more likely to have someone 
else collect their drugs at the pharmacy.
187
 Because it is not possible to opt out of 
national registers in Sweden, there is no selective non-response group in the 
studies described in this thesis. However, persons that were not identified 
through the SPDR (did not use a drug) will probably be different from the 
persons that were identified (used a drug). 
In all the studies, we used the SPDR to identify persons to whom a drug was 
prescribed and dispensed during the study window; these people made up the 
study population. In old age, the vast majority of people are regularly dispensed 
at least one drug, and compared to Statistics Sweden’s registration of the total 
population, we capture about 90% of the octogenarians, 94% of the 
nonagenarians and 94% of the centenarians (from Study I). Thus, coverage of 
older adults in the Swedish population was good in these studies. People not 
included in the study population were probably healthier than those who were 
included, because they did not use a drug.  
Drugs provided by hospitals and nursing home supply rooms are not included in 
the SPDR. In most counties in Sweden, drugs provided by nursing home supply 
rooms account for less than 1% of the total drug use in people 80 years or older. 
However, in Stockholm County, as many as 10% of prescribed drugs were 
distributed from nursing home supply rooms in 2006.
188
 Furthermore, since 
drugs used at hospitals are not included in the SPDR, some people with severe 
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diseases will not be included in the register. These persons will most likely have 
poorer health than those included in the SPDR. 
In studies II and III, we investigated associations in disease-specific subgroups. 
The subgroups included those identified in the SPR as having a diagnosis of 
dementia and/or using an anti-dementia drug in the SPDR, or having 
experienced osteoporosis-related fractures according to SPR. Because the 
sensitivity of the registers can be low, especially for dementia,
189
 the number of 
people with dementia may have been underestimated, which would result in the 
inclusion of too few cases in the subgroup analysis. A better estimation of the 
prevalence of dementia would have been possible if we had data from primary 
care and not only inpatient diagnoses.
190
 However, specificity is high,
189
 so 
people in the subgroup analyses probably really had dementia as indicated by 
SPR data. It is unclear how this selection bias, the low sensitivity of dementia 
from SPR and SPDR, would affect the results. 
However, the high coverage of the Swedish older-adult population in the 
nationwide registers, provided data in which potential selection biases should be 
smaller than that in most other observational studies. 
6.4.2 Misclassification of outcome 
Misclassification arises when the information collected about a person in a study 
is erroneous. Misclassification can be either differential or non-differential. 
Differential classification occurs when misclassification is in some way 
dependent on some other important variable.
185
 Non-differential 
misclassification is likely to affect any epidemiological study and will most 
likely lead to an attenuation of associations. The outcome of the studies in this 
thesis was drug use. Information about drug use was collected and registered at 
Swedish pharmacies when the drugs were actually dispensed. As dispensed 
drugs were the outcome measure, the risk of misclassification was thus very low. 
Adherence to medications is a problem in many studies of drug use. Non-
adherence can occur at initiation of treatment (primary-non-adherence), in the 
implementation of treatment and as discontinuation of treatment.
159
 Initiation of 
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treatment includes the actual dispensing of a drug prescribed by a physician. 
Using the SPDR, it is only possible to study drugs that have been dispensed, not 
drugs that have been prescribed. Implementation refers to the process whereby 
the patients’ use of a drug actually corresponds to the suggested dosing regimen. 
Discontinuation refers to the situation in which a patient discontinues therapy 
prematurely. Implementation-related non-adherence and premature 
discontinuation of therapy are difficult or impossible to study with data from the 
SPDR. However, implementation and discontinuation are of minor relevance to 
the present thesis. 
Studies show that adherence rates are low for many drugs. Among osteoporosis 
drug users, 20% to 30% discontinue their treatment after 6 to 12 months.
191
 In 
this thesis, it is primarily non-initiation (primary non-adherence) that could have 
introduced bias. Social differences in the use of a variety of drugs are the main 
outcome in this thesis, and it is possible that the associations between social 
groups and drug use might be explained by differences in patients’ drug-
collecting rates rather than physicians’ prescribing rates. Previous studies have 
shown that primary non-adherence among older adults in Sweden differs by 
socioeconomic position.
160
 However, research on the relationship between 
adherence rates and SEP has generally been inconclusive.
192, 193
 Additionally, 
regardless of their socioeconomic group, older patients are less likely than 
younger patients to discontinue a drug therapy because of increases in price.
130
 
Non-initiation/primary non-adherence can be one mechanism underlying the 
association between sociodemographic factors and the use of drugs. 
6.4.3 Misclassification of exposure 
In the studies in this thesis, the main exposures were age and education. Age was 
classified using the individuals’ personal identification numbers and was 
probably not affected by misclassification. 
Data on education was obtained from the SER. At the time we obtained the data 
for these studies, SER only included information on persons under the age of 75 
years. Thus, we had to collect data retrospectively from the register to obtain 
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data on education for persons older than 75 years. If people increased their level 
of education after the age of 75, we underestimated their level of education. 
Further, SER does not have complete data on education completed outside of 
Sweden.
167
 However, for persons in the cohorts in this study, this was likely a 
minor issue. 
Similarly to the selection bias that can arise in disease-specific subgroup 
analyses (the dementia and fracture subgroup analyses described in 6.4.1 
Selection bias), adjustments for the diseases in the total study population can 
introduce a bias, but this bias will then be a misclassification of exposure rather 
than a selection bias. 
6.4.4 Confounding 
A confounding factor is a factor associated with both the dependent and 
independent variable that can lead to spurious associations between the 
dependent and independent variable when not included in the analyses.
185
 
Most notable in pharmacoepidemiological studies is confounding by indication. 
This occurs when the association between drug use and the outcomes are 
confounded by the underlying disease the drug is intended to treat.
194, 195
 
Confounding by indication is foremost a problem in studies of the intended or 
unintended effects of drugs. However, it also bears some relevance in studies of 
SEP or age and their relation to drug use. If the disease panorama is different in 
different social groups, the indication of a certain drug can also differ between 
the groups. Thus, the results regarding inequality in drug use could be dependent 
on the underlying disease pattern rather than differences in prescribing. 
In this thesis, 'number of drugs' was used to adjust for overall co-morbidity. 
Researchers have shown that using this indicator as a proxy measure of co-
morbidities is comparable to using other proxy measures of co-morbidities.
172
 
However, residual confounding is inevitable because the number of drugs 
prescribed to and collected by a person does not completely reflect health 
status.
171
 Further, in the instances when we have used diagnoses from the SPR 
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(studies II and IV) we do not know the severity of the diseases, and disease 
severity could be an important confounder. 
Education was the only indicator of SEP used in the present thesis. SEP can be 
measured with other indicators as well, such as income and social class.
94
 These 
three indicators partially overlap; however, the empirical and theoretical 
underpinnings of the three indicators are not the same.
95, 196
 Including other 
indicators of SEP would have allowed for a more refined analysis of other 
dimensions of SEP. However, one advantage of using education as an indicator 
of SEP in old age is that it is not affected by retirement (which impacts both 
income and occupation). 
Personal characteristics, such as cognitive ability and personality, could also be 
an important link between socioeconomic conditions and drug use. Researchers 
have suggested that as intergenerational social mobility has increased, 
intelligence and favourable personality traits have become increasingly 
important to acquiring higher socioeconomic positions.
78
 Cognitive ability and 
personality is likely to influence drug use at many points in the process of drug 
use, from health-information seeking to the patient-physician interaction. 
Gender differences are not a main focus of this thesis but have been considered 
in all studies in the thesis. Gender differences in drug use are an important topic 
of study in their own right. In the context of this thesis, it is also important to 
note that gender differences exist in health, mortality and educational attainment 
of the cohorts studied. In older cohorts, women tend to have lower educational 
attainment than men, which is why it is important to consider gender in analyses 
of socioeconomic inequalities. Further, the gender paradox of health and 
mortality (i.e., women live longer but have more health problems)
32
 means that 
women are often in majority in study samples of older adults but also tend to use 
more drugs than men of the same age.  
On the one hand, register-based research often provides the opportunity to study 
very large and unselected populations with high statistical precision. On the 
other hand, the information is often restricted to a few variables. Potential 
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confounders relevant to this work on which information was not available in the 
registers included self-rated health, function, cognitive status, lifestyle factors 
and caregiver support. A more comprehensive set of variables would both have 
reduced the risk for spurious results and enabled a more refined analysis of the 
underlying mechanisms that lead to inequality in prescribing. 
6.5 CONCLUSIONS 
This thesis contributes to the knowledge about how the sociodemographic 
factors like SEP and age are related to drug use. The importance of equal access 
to drugs, regardless of sociodemographic factors, should be highlighted in social 
policy. 
We demonstrated that low SEP is associated with increased risk, in old age, of 
inappropriate prescribing of antipsychotic drugs to persons with dementia, a 
lower risk of being prescribed potentially beneficial osteoporosis drugs after a 
fracture, and a lower risk of being prescribed psychotropic drugs by a physician 
specialised in geriatrics or psychiatry. 
In general, low SEP seems to be associated with less optimal drug treatment. The 
association seems fairly consistent across different outcomes. However, the 
mechanisms linking lower SEP to suboptimal drug treatment are probably 
complex and need to be addressed in further studies. In this thesis, unequal drug 
use was also found among persons with low cognitive abilities (dementia), which 
supports that other mechanisms should be sought in addition to those that relate 
to individuals' abilities to seek and demand health care. Further, we found 
unequal treatment with osteoporosis drugs both before and after the occurrence 
of a fracture, which suggests that the health care system does not ameliorate the 
socioeconomic differences in preventive use of osteoporosis drugs. Finally, 
differences in the prescription of psychotropics by specialised physicians to 
people from different socioeconomic groups may indicate that higher 
socioeconomic groups have better access to specialists, which could be a 
mechanism that links lower SEP to less optimal drug use. 
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We found that differences in the geographical area of residence were associated 
with drug use. Access to specialised prescribing by geriatricians was more 
closely related to living in a metropolitan area than to the educational level of the 
patient. Geographical variations are likely to be an important mediator between 
SEP and drug use but can also have an independent effect on drug use. 
Older age was also related to less optimal drug treatment. However, the 
associations were not as consistent as for SEP. Furthermore, we found that the 
general perception that the number of drugs increases with age was false at 
extremely high ages; the number of drugs prescribed seemed rather to level off 
around 95 years of age. 
The present findings have several policy implications. It is clear that there are 
differences in drug use that are not related to disease, and efforts should be made 
to prevent such inequality. However, because the mechanisms that link 
sociodemographic factors to drug use are far from understood, it is unclear how 
to best implement policies to reduce sociodemographic differences in drug use. 
Furthermore, as more people get to live longer, many will also spend long 
periods in the end of their lives in poor health using many medications. Both 
research and policy should address drug use in older age, in order to reduce drug-
related problems and to increase the quality and knowledge of drug therapy 
among older adults. 
6.6 FUTURE DIRECTIONS 
The present results indicate that sociodemographic differences in drug use in 
older people are rather consistent – an empirical regularity. The next step should 
therefore be to better explore the mechanisms underlying the association 
between sociodemographic factors and drug use in older people. First, more 
detailed data are needed; that is, data that make it is possible to explore how age 
and SEP interrelate with other possible confounders. Moreover, it is also 
important to investigate the extent to which primary adherence affects the 
associations; i.e., the extent to which sociodemographic differences in drug use 
reflect differences in prescribing as opposed to differences in dispensing. 
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Second, prescribing is ultimately a consequence of health care use. There is a 
large literature on equity in health care use, but relatively little has been written 
about equity in drug treatment. Thus, studies of inequality in drug use should 
rely more on the extensive literature on equity in health care, and drug use 
should more regularly be included in studies of health care use. 
Last, the SPDR was initiated in 2005, and it is now possible to follow individual 
drug use over an extensive period of time. Longitudinal studies of drug use will 
provide a golden opportunity to better understand the complexity of this issue. 
Such studies will make it possible to study drug use as people age so that we can 
better understand the complex process of initiation and discontinuation of drug 
treatments. Linking the SPDR to other registers will provide insight into how 
drug use changes as a consequence of health, living situation and other 
sociodemographic factors. 
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